Skip Ribbon Commands
Skip to main content
Menu

Clin Assoc Prof Ho Yew Leng Aloysius

Dr Aloysius Ho from SGH

Clin Assoc Prof Ho Yew Leng Aloysius

MBBS, MMed(Int Med), FRCP, FRCPath(UK)

Senior Consultant

Specialty: Haematology, Haematology

Sub-specialties: Haematopoietic Stem Cell & Cellular Therapy, Acute Leukemia

Conditions Treated by this Doctor:
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndromes.

Clinical Appointments

  • Medical Director, Singapore Cord Blood Bank
  • Head & Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Director of Cell Transplant, SD Transplant Centre, Programme Director, Haematopoietic Stem Cell (Adult) & Umbilical Cord Transplant Programme and Senior Consultant SingHealth Duke-NUS Transplant Centre
  • Senior Consultant Haematology Singapore General HospitalSingapore General Hospital

Profile

Dr Ho graduated with a Bachelor of Medicine and Surgery from the University of Adelaide and a Master of Medicine from the National University of Singapore. He is a Fellow of the Royal College of Physicians (London) and of the Royal College of Pathologists. He completed his training in Haematology at King’s College Hospital in London and was Consultant Haematologist in King’s before he joined SGH.

Dr Ho has an interest in haematopoietic stem cell transplantation, the myelodysplastic syndromes and other bone marrow failure syndromes and acute myeloid leukaemia.

Education

  • ​University of Adelaide, South Australia

Professional Appointments and Committee Memberships

  • Adjunct Associate Professor Duke-NUS Graduate Medical School
  • Clinical Senior Lecturer, YLL School of Medicine
  • Medical Director, Singapore Cord Blood Bank
  • Programme Director, Haematopoietic Stem Cell Transplant Programme, Singapore General Hospital, Singapore 
  • Director of Clinical Services, Singhealth Duke-NUS Blood Cancer Centre

Awards

Research Interests

  • Myelodysplastic Syndrome/Bone marrow failure syndromes
  • Haematopoietic Progenitor Cell Transplantation
  • Immune effector cell therapy

Publications

  • Wang L, Allen J, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Lim F, Oon L, Tan TT, Linn YC, Tan BH. Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center: Predictive value of the immunodeficiency scoring index. Transpl Infect Dis. 2017 Mar 10. doi:10.1111/tid.12693. [Epub ahead of print] PubMed PMID: 28295964.
  • Zhou W, Sultana R, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Koh LP,Koh M, Loh Y, Tan P, Linn YC. Long term renal outcome after allogeneic haemopoietic stem cell transplant: A comprehensive analysis of risk factors in an  Asian patient population. Clin Transplant. 2017 Jan 30. doi: 10.1111/ctr.12920. [Epub ahead of print] PubMed PMID:                            28135776. 
  • Maka VV, Koh LP, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Koh M, Lim F, Lim ZY, Loh Y, Poon M, Del Rosario DR, Tai BC, Tan LK, Tan P, Linn YC. An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. Bone Marrow Transplant. 2016 Oct 31. doi: 10.1038/bmt.2016.286. [Epub ahead of print] PubMed PMID: 27797364.
  • Kumar R, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, Pasquini M, Miyamura K, Kato K, Yoshimi A, Inamoto Y, Ichinohe T, Wood WA Jr, Wirk B, Seftel M,Rowlings P, Marks DI, Schultz KR, Gupta V, Dedeken L, George B, Cahn JY, Szer J, Lee JW, Ho AY, Fasth A, Hahn T, Khera N, Dalal J, Bonfim C, Aljurf M, Atsuta Y, Saber W. Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biol Blood Marrow Transplant. 2016 May;22(5):932-40 PubMed PMID: 26797402.
  • Ong SY, de Mel S, Chen YX, Ooi MG, Surendran S, Lin A, Koh LP, Linn YC, Ho AY, Hwang WY, Phipps C, Loh SM, Goh YT, Tan D, Chng WJ, Gopalakrishnan SK. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. Bone Marrow Transplant. 2016 Mar 14. doi: 10.1038/bmt.2016.43. [Epub ahead of print] PubMed PMID: 26974274
  • SY Ong, C Phipps, P Chu, A Prasath, AYL Ho, SJ Sobak, W Hwang. Cord blood unit factors influencing transplant outcomes from the Asian multiethnic Singapore Cord Blood Bank. Bone Marrow Transplantation advance online publication, 8 June 2015; doi:10.1038/bmt.2015.134 
  • Ma L, Hao S, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Koh LP, Koh M, Lim ZY, Loh Y, Poon M, Tan LK, Tan P, Linn YC. Pre-transplant Achievement of Negativity in Minimal Residual Disease and FAB-L1 Morphology Predict Superior
  • Outcome after Allogeneic Transplant for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia- an analysis of Southeast Asian Patients. Leuk Lymphoma. 2014 Aug 20:1-21. [Epub ahead of print] PubMed PMID: 25139689.
  • Ma L, Hao S, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Koh LP, Koh M, Lim ZY, Loh Y, Poon M, Tan LK, Tan P, Linn YC. WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients. Ann Hematol. 2014 Dec 18. [Epub ahead of print] PubMed PMID: 25519475.
  • Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, deLavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ. Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8. PubMed PMID: 24216184.
  • Kirwan M, Walne AJ, Plagnol V, Velangi M, Ho A, Hossain U, Vulliamy T, Dokal. Exome Sequencing Identifies Autosomal-Dominant SRP72 Mutations Associated with Familial Aplasia and Myelodysplasia. Am J Hum Genet. 2012 May 4;90(5):888-92. Epub 2012 Apr 26. PubMed PMID: 22541560. 
  • Lim ZY, Fiaccadori V, Gandhi S, Hayden J, Kenyon M, Ireland R, Marsh J, Ho AY, Mufti GJ, Pagliuca A. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res. 2009 Nov 25. 
  • Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S, Marsh J, Mufti GJ, Pagliuca A. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant. 2009 Sep 21. 
  • Krishnamurthy P, Lim ZY, Nagi W, Kenyon M, Mijovic A, Ireland R, Marsh J, Ho AY, Mufti GJ, Pagliuca A. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant. 2010 Oct;45(10):1502-7. 
  • Judith C Marsh, Gupta Vikas, Ziyi Lim, Aloysius Y Ho, Robin Ireland, Janet Hayden, Victoria Potter, Mickey B Koh, Serajul M Islam, Nigel H Russell, David I Marks, Ghulam J Mufti, and Antonio Pagliuca. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011 Aug 25;118(8):2351-7. Epub 2011 Apr 25
  • Nagi W, Lim ZY, Krishnamurthy P, Potter V, Tindell V, Reiff-Zall L, Abdullah A, Lea N, Kenyon M, Marsh J, Ho AY, Mufti GJ, Pagliuca A. Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. Leuk Res. 2011 Aug;35(8):998-1000.
  • Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NS, Mufti  GJ.  CDKN2B methylation status and isolated chromosome 7 abnormalities predict  responses to treatment with 5-azacytidine. Leukemia. 2007 Sep;21(9):1937-44. Epub 2007 Jul 5. 
  • Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, Tobal K, Devereux S, Pagliuca A, Mufti GJ.  Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol. 2007 Aug;138(4):517-26. Epub 2007 Jun 29. 
  • Creamer D, Martyn-Simmons CL, Osborne G, Kenyon M, Salisbury JR, Devereux S, Pagliuca A, Ho AY, Mufti GJ, du Vivier AW. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. Arch Dermatol. 2007 Sep;143(9):1157-62.
  • Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kroger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, Lopez-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H.  Impact of the intensity of the pre-transplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the infectious diseases working party of the european group for blood and marrow transplantation. Blood. 2006 May 23.
  • Lim ZY, Ho AY, Ingram W, Kenyon M, Pearce L, Czepulkowski B, Devereux S, Duarte RF, Pagliuca A, Mufti GJ. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol. 2006 Oct;135(2):201-9. Epub 2006 Aug 25 
  • Ramasamy K, Lim ZY, Pagliuca A, Grundy R, Devereux S, Ho AY, Mufti GJ. Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006 Oct 23. 
  • AYL Ho, A Pagliuca, M Kenyon, I El-Hemaidi, S Devereux, GJ Mufti.  Reduced-intensity allogeneic haematopoietic stem cell transplantation with alemtuzumab (CAMPATH-1H) conditioning regimens; survival does not plateaux till Day +200 [letter]. Blood 2003; 101(2):  779-780.
  • AYL Ho, S Devereux, GJ Mufti, A Pagliuca. Reduced-intensity Rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible & induces durable molecular remissions. Bone Marrow Transplantation 2003; 31(7): 551-557.
  • AYL Ho, S Devereux, A Pagliuca, GJ Mufti. Post-transplant lymphoproliferative disorders following reduced intensity conditioning with in-vivo T-cell depletion [letter]. Bone Marrow Transplantation 2003; 31(8): 727.
  • Mufti G, List AF, Gore SD, Ho AYL. Myelodysplastic Syndrome. Hematology. 2003;2003:176-199.
  • Faulkner RD, Craddock C, Byne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, LiuYin J, Russell NH. BEAM-CAMPATH reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GvHD, toxicity and survival in 65 patients. Blood 2004; 103(2): 428-34.
  • AYL Ho, A Pagliuca, M Kenyon, JE Parker, A Mijovic, S Devereux, GJ Mufti. Reduced-intensity allogeneic haematopoietic stem cell transplantation for poor prognosis myelodysplastic syndromes and acute myeloid leukaemia with multilineage dysplasia using Fludarabine, Busulphan and Alemtuzumab (CAMPATH-1H) conditioning. Blood. 2004 Sep 15;104(6):1616-23.

Research Trials